CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present third quarter 2017 results to investors and analysts in a conference call on October 31, 2017 at 8:30am EDT, hosted by Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, John Leonard, M.D., Executive Vice President, R&D, and Graeme Bell, Chief Financial Officer. The analyst and investor presentation can be downloaded starting at 8:00am EDT from the Investor Relations section of the company’s website at www.intelliatx.com. A replay of the call will be available on Intellia’s website, beginning on October 31 at 11:00am EDT, 2017.
To participate on the day of the call:
- U.S. callers should dial 888-752-0423 and use Conference ID# 9089048, approximately five minutes before the call.
- International callers should dial +1 918-398-4936 and use Conference ID# 9089048, approximately five minutes before the call.
To listen to the replay:
- U.S. callers should dial 855-859-2056, Conference ID# 9089048.
- International callers should dial +1 404-537-3406, Conference ID# 9089048.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, pot curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets
Vice President, Investor Relations
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
Source:Intellia Therapeutics, Inc.